Summary
Updated Aug 31, 2026
Thomas Patrick Kelly is Chief Financial Officer of Xenon Pharmaceuticals Inc. (XENE). 1 SEC Form 4 filing on record, dated 15 October 2025.
Trading Pattern
InsiderAlpha's records for Thomas Patrick Kelly go back to 2025: 1 primary Form 4 filing, an average of 0.5 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Thomas Patrick Kelly files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Ian Mortimer - $21.30M of XENE open-market activity in the last 12 months
- Steven Gannon - $641K of XENE open-market activity in the last 12 months
- Christopher John Kenney - $244K of XENE open-market activity in the last 12 months
- Andrea Difabio - $231K of XENE open-market activity in the last 12 months
- Gary Patou - $70K of XENE open-market activity in the last 12 months
- Gillian Cannon - $63K of XENE open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Thomas Patrick Kelly?
Thomas Patrick Kelly is a corporate insider, tracked as Chief Financial Officer of Xenon Pharmaceuticals Inc. (XENE). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Thomas Patrick Kelly last file a Form 4?
The only primary Form 4 on record is dated 15 October 2025.
Where can I see all of Thomas Patrick Kelly's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Thomas Patrick Kelly and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial